Anxiolytics & Sedatives

Alprazolam is a short-acting, high-potency triazolobenzodiazepine. It enhances the binding affinity of the major inhibitory neurotransmitter GABA to GABAA receptors, opening neuronal chloride ion channels, hyperpolarizing membranes, and producing rapid anxiolytic, sedative, muscle-relaxant, and anticonvulsant effects. Indicated for acute management of generalized anxiety disorder (GAD) and panic disorder with or without agoraphobia.

Alprazolam is a short-acting, high-potency triazolobenzodiazepine. It enhances the binding affinity of the major inhibitory neurotransmitter GABA to GABAA receptors, opening neuronal chloride ion channels, hyperpolarizing membranes, and producing rapid anxiolytic, sedative, muscle-relaxant, and anticonvulsant effects. Indicated for acute management of generalized anxiety disorder (GAD) and panic disorder with or without agoraphobia.

Betahistine is a synthetic structural histamine analogue that acts as a strong antagonist at histamine H3 receptors and a weak agonist at histamine H1 receptors. By blocking H3 autoreceptors in the inner ear and vestibular nuclei, it enhances local histamine release, dilating precapillary sphincters in the stria vascularis and microvasculature of the labyrinth, thereby reducing endolymphatic hydrops pressure. Indicated for Meniere's disease (characterized by the triad of vertigo, tinnitus, and sensorineural hearing loss) and symptomatic vestibular vertigo.

Clonazepam is a long-acting benzodiazepine with potent anticonvulsant, muscle-relaxant, and anxiolytic actions on the WHO Model List of Essential Medicines. It allosterically modulates GABAA receptors, increasing frequency of chloride channel opening and dampening epileptic foci in the cortex and limbic system. Indicated for panic disorder with or without agoraphobia, Lennox-Gastaut syndrome, myoclonic and akinetic seizures, and absence seizures refractory to succinimides.

Diazepam is a prototype long-acting 1,4-benzodiazepine on the WHO Model List of Essential Medicines. It binds to the GABAA receptor complex in the limbic system, thalamus, and hypothalamus, facilitating GABA-mediated inhibitory neurotransmission. Possesses an active desmethyldiazepam metabolite with a prolonged elimination half-life (up to 100 hours). Indicated for management of anxiety disorders, acute alcohol withdrawal syndrome (delirium tremens), skeletal muscle spasm, and status epilepticus.

Clonazepam and Escitalopram is a premier neuropsychiatric fixed-dose combination. Escitalopram, a high-affinity SSRI, selectively inhibits presynaptic serotonin reuptake to treat core depression and panic circuitry over time, while clonazepam, a long-acting benzodiazepine, delivers immediate allosteric enhancement of GABAA receptors, dampening initial SSRI-induced jitteriness, insomnia, and acute anxiety. Indicated for major depressive disorder with comorbid anxiety, panic disorder, and generalized anxiety disorder.

Etizolam is a thienodiazepine derivative structurally related to benzodiazepines. It acts as a potent full agonist at the GABAA receptor, producing significant anxiolytic, sedative-hypnotic, anticonvulsant, and muscle-relaxant actions with 6- to 10-fold higher potency than diazepam. Indicated for short-term management of generalized anxiety disorder, panic disorder, and insomnia associated with anxiety.

Alprazolam and Fluoxetine combines a fast-acting triazolobenzodiazepine with a selective serotonin reuptake inhibitor (SSRI). Alprazolam rapidly relieves acute psychic anxiety, insomnia, and agitation within hours, while fluoxetine provides sustained long-term modulation of central serotonergic pathways to treat underlying depressive and panic pathology over weeks. Indicated for major depressive disorder with comorbid anxiety or agitation.

Clonazepam is a long-acting benzodiazepine with potent anticonvulsant, muscle-relaxant, and anxiolytic actions on the WHO Model List of Essential Medicines. It allosterically modulates GABAA receptors, increasing frequency of chloride channel opening and dampening epileptic foci in the cortex and limbic system. Indicated for panic disorder with or without agoraphobia, Lennox-Gastaut syndrome, myoclonic and akinetic seizures, and absence seizures refractory to succinimides.

Diazepam is a prototype long-acting 1,4-benzodiazepine on the WHO Model List of Essential Medicines. It binds to the GABAA receptor complex in the limbic system, thalamus, and hypothalamus, facilitating GABA-mediated inhibitory neurotransmission. Possesses an active desmethyldiazepam metabolite with a prolonged elimination half-life (up to 100 hours). Indicated for management of anxiety disorders, acute alcohol withdrawal syndrome (delirium tremens), skeletal muscle spasm, and status epilepticus.

Lorazepam is a high-potency, intermediate-acting 3-hydroxy benzodiazepine on the WHO Model List of Essential Medicines. It enhances GABA-mediated synaptic inhibition by binding to GABAA receptors. Because it undergoes direct hepatic glucuronidation to inactive metabolites without intermediate oxidative CYP450 steps, it is the benzodiazepine of choice in patients with hepatic impairment and the elderly. Indicated for short-term management of severe anxiety, insomnia associated with anxiety, acute status epilepticus, and pre-anesthetic sedation.

Lorazepam is a high-potency, intermediate-acting 3-hydroxy benzodiazepine on the WHO Model List of Essential Medicines. It enhances GABA-mediated synaptic inhibition by binding to GABAA receptors. Because it undergoes direct hepatic glucuronidation to inactive metabolites without intermediate oxidative CYP450 steps, it is the benzodiazepine of choice in patients with hepatic impairment and the elderly. Indicated for short-term management of severe anxiety, insomnia associated with anxiety, acute status epilepticus, and pre-anesthetic sedation.

Nitrazepam is an intermediate-to-long-acting nitrobenzodiazepine hypnotic agent. It binds to the GABAA receptor complex, increasing chloride conductance, hyperpolarizing neuronal membranes, and suppressing the brainstem reticular activating system, shortening sleep latency and reducing nocturnal awakenings. Indicated for short-term severe, disabling insomnia and infantile spasms (West syndrome).

Zolpidem Tartrate is an imidazopyridine non-benzodiazepine hypnotic agent. It binds selectively with high affinity to the alpha-1 subunit-containing GABAA receptor subtype (omega-1 receptor) in the brain, sparing alpha-2 and alpha-3 subunits, resulting in potent sleep-inducing action with minimal myorelaxant and anticonvulsant effects. Indicated for short-term treatment of insomnia characterized by difficulties with sleep initiation.

Cinnarizine is a piperazine-derivative labyrinthine sedative and peripheral vasodilator. It selectively blocks voltage-gated T-type calcium channels, inhibiting trans-membrane calcium influx in vestibular sensory cells and vascular smooth muscle, improving labyrinthine microcirculation and suppressing motion-induced vestibular overstimulation. Indicated for vestibular vertigo, motion sickness prophylaxis, and peripheral vascular disorders.

Chlordiazepoxide is the historical first-discovered benzodiazepine. It acts by binding to stereospecific GABAA receptors in the central nervous system, enhancing chloride ion channel opening and augmenting GABA-mediated neuronal inhibition. Possesses active metabolites with a long elimination half-life. Indicated for short-term relief of severe anxiety disorders and acute management of alcohol withdrawal symptoms.

Clonazepam and Escitalopram is a premier neuropsychiatric fixed-dose combination. Escitalopram, a high-affinity SSRI, selectively inhibits presynaptic serotonin reuptake to treat core depression and panic circuitry over time, while clonazepam, a long-acting benzodiazepine, delivers immediate allosteric enhancement of GABAA receptors, dampening initial SSRI-induced jitteriness, insomnia, and acute anxiety. Indicated for major depressive disorder with comorbid anxiety, panic disorder, and generalized anxiety disorder.

Betahistine is a synthetic structural histamine analogue that acts as a strong antagonist at histamine H3 receptors and a weak agonist at histamine H1 receptors. By blocking H3 autoreceptors in the inner ear and vestibular nuclei, it enhances local histamine release, dilating precapillary sphincters in the stria vascularis and microvasculature of the labyrinth, thereby reducing endolymphatic hydrops pressure. Indicated for Meniere's disease (characterized by the triad of vertigo, tinnitus, and sensorineural hearing loss) and symptomatic vestibular vertigo.

Betahistine is a synthetic structural histamine analogue that acts as a strong antagonist at histamine H3 receptors and a weak agonist at histamine H1 receptors. By blocking H3 autoreceptors in the inner ear and vestibular nuclei, it enhances local histamine release, dilating precapillary sphincters in the stria vascularis and microvasculature of the labyrinth, thereby reducing endolymphatic hydrops pressure. Indicated for Meniere's disease (characterized by the triad of vertigo, tinnitus, and sensorineural hearing loss) and symptomatic vestibular vertigo.

Chlordiazepoxide and Amitriptyline is a classic psychotropic formulation combining a benzodiazepine with a tricyclic antidepressant (TCA). Chlordiazepoxide provides prompt reduction of psychic tension, anxiety, and agitation via GABAA receptor enhancement, while amitriptyline inhibits the neuronal reuptake of norepinephrine and serotonin to resolve underlying depressive illness. Indicated for moderate-to-severe depression associated with prominent anxiety, agitation, and insomnia.

Cinnarizine is a piperazine-derivative labyrinthine sedative and peripheral vasodilator. It selectively blocks voltage-gated T-type calcium channels, inhibiting trans-membrane calcium influx in vestibular sensory cells and vascular smooth muscle, improving labyrinthine microcirculation and suppressing motion-induced vestibular overstimulation. Indicated for vestibular vertigo, motion sickness prophylaxis, and peripheral vascular disorders.

Alprazolam and Propranolol Hydrochloride is a synergistic psychotropic-cardiovascular formulation combining a triazolobenzodiazepine with a non-selective beta-adrenergic blocker. Alprazolam enhances central inhibitory GABAergic neurotransmission at the GABAA receptor, relieving psychological panic and tension, while propranolol competitively antagonizes peripheral beta-1 and beta-2 adrenergic receptors, curbing somatic autonomic manifestations of anxiety (palpitations, resting tachycardia, tremors, sweating). Indicated for situational anxiety, panic disorder with severe autonomic hyperactivity, and performance anxiety.

Alprazolam and Propranolol Hydrochloride is a synergistic psychotropic-cardiovascular formulation combining a triazolobenzodiazepine with a non-selective beta-adrenergic blocker. Alprazolam enhances central inhibitory GABAergic neurotransmission at the GABAA receptor, relieving psychological panic and tension, while propranolol competitively antagonizes peripheral beta-1 and beta-2 adrenergic receptors, curbing somatic autonomic manifestations of anxiety (palpitations, resting tachycardia, tremors, sweating). Indicated for situational anxiety, panic disorder with severe autonomic hyperactivity, and performance anxiety.

Alprazolam and Sertraline pairs an immediate-acting high-potency benzodiazepine with an SSRI. Alprazolam bridges the initial 2-4 week lag phase of antidepressant therapy by rapidly controlling severe anxiety, panicky distress, and insomnia, while sertraline elevates synaptic serotonin to alleviate core depressive illness. Indicated for major depressive episodes accompanied by prominent anxiety symptoms.

Alprazolam and Sertraline pairs an immediate-acting high-potency benzodiazepine with an SSRI. Alprazolam bridges the initial 2-4 week lag phase of antidepressant therapy by rapidly controlling severe anxiety, panicky distress, and insomnia, while sertraline elevates synaptic serotonin to alleviate core depressive illness. Indicated for major depressive episodes accompanied by prominent anxiety symptoms.

Chlordiazepoxide and Amitriptyline is a classic psychotropic formulation combining a benzodiazepine with a tricyclic antidepressant (TCA). Chlordiazepoxide provides prompt reduction of psychic tension, anxiety, and agitation via GABAA receptor enhancement, while amitriptyline inhibits the neuronal reuptake of norepinephrine and serotonin to resolve underlying depressive illness. Indicated for moderate-to-severe depression associated with prominent anxiety, agitation, and insomnia.

Chlordiazepoxide is the historical first-discovered benzodiazepine. It acts by binding to stereospecific GABAA receptors in the central nervous system, enhancing chloride ion channel opening and augmenting GABA-mediated neuronal inhibition. Possesses active metabolites with a long elimination half-life. Indicated for short-term relief of severe anxiety disorders and acute management of alcohol withdrawal symptoms.

Cinnarizine and Dimenhydrinate is a dual-target vestibular formulation. Cinnarizine acts as a selective T-type calcium channel blocker, inhibiting calcium influx into vestibular sensory hair cells and dampening labyrinthine hyper-reactivity, while dimenhydrinate (diphenhydramine-theoclate salt) blocks H1 receptors in the vestibular nuclei and solitary tract, suppressing the vegetative emetic reflex. Together, they provide synergistic peripheral and central vestibular suppression. Indicated for the symptomatic treatment of various origins of vertigo in adults.

Clonazepam is a long-acting benzodiazepine with potent anticonvulsant, muscle-relaxant, and anxiolytic actions on the WHO Model List of Essential Medicines. It allosterically modulates GABAA receptors, increasing frequency of chloride channel opening and dampening epileptic foci in the cortex and limbic system. Indicated for panic disorder with or without agoraphobia, Lennox-Gastaut syndrome, myoclonic and akinetic seizures, and absence seizures refractory to succinimides.

Diazepam is a prototype long-acting 1,4-benzodiazepine on the WHO Model List of Essential Medicines. It binds to the GABAA receptor complex in the limbic system, thalamus, and hypothalamus, facilitating GABA-mediated inhibitory neurotransmission. Possesses an active desmethyldiazepam metabolite with a prolonged elimination half-life (up to 100 hours). Indicated for management of anxiety disorders, acute alcohol withdrawal syndrome (delirium tremens), skeletal muscle spasm, and status epilepticus.

Diazepam is a prototype long-acting 1,4-benzodiazepine on the WHO Model List of Essential Medicines. It binds to the GABAA receptor complex in the limbic system, thalamus, and hypothalamus, facilitating GABA-mediated inhibitory neurotransmission. Possesses an active desmethyldiazepam metabolite with a prolonged elimination half-life (up to 100 hours). Indicated for management of anxiety disorders, acute alcohol withdrawal syndrome (delirium tremens), skeletal muscle spasm, and status epilepticus.

Etizolam is a thienodiazepine derivative structurally related to benzodiazepines. It acts as a potent full agonist at the GABAA receptor, producing significant anxiolytic, sedative-hypnotic, anticonvulsant, and muscle-relaxant actions with 6- to 10-fold higher potency than diazepam. Indicated for short-term management of generalized anxiety disorder, panic disorder, and insomnia associated with anxiety.

Clonazepam is a long-acting benzodiazepine with potent anticonvulsant, muscle-relaxant, and anxiolytic actions on the WHO Model List of Essential Medicines. It allosterically modulates GABAA receptors, increasing frequency of chloride channel opening and dampening epileptic foci in the cortex and limbic system. Indicated for panic disorder with or without agoraphobia, Lennox-Gastaut syndrome, myoclonic and akinetic seizures, and absence seizures refractory to succinimides.

Etizolam and Propranolol is a psychotropic and autonomic regulator combination pairing a thienodiazepine with a non-selective beta-blocker. Etizolam acts as a full agonist at central GABAA receptors to suppress emotional distress and anticipatory anxiety, while propranolol blocks peripheral beta-adrenergic receptors to eliminate somatic symptoms (tachycardia, palpitations, sweating, tremors). Indicated for situational anxiety, autonomic anxiety manifestations, panic disorder, and tension headache.

Midazolam is an ultra-short-acting imidazobenzodiazepine with rapid onset and potent sedative, anxiolytic, amnesic, and anticonvulsant properties. It enhances GABAA receptor opening, depressing the central nervous system. Indicated parenterally for pre-operative sedation, conscious sedation during diagnostic/surgical procedures, induction of general anesthesia, and status epilepticus in intensive care units.

Clonazepam and Desvenlafaxine Extended-Release pairs an active SNRI metabolite with a long-acting benzodiazepine. Desvenlafaxine inhibits neuronal reuptake of both serotonin and norepinephrine to reverse core neurochemical deficits in depression, while clonazepam mitigates acute agitation, panic, and sleep disturbances during therapy induction. Indicated for major depressive disorder with prominent anxiety and severe somatic distress.

Clonazepam and Desvenlafaxine Extended-Release pairs an active SNRI metabolite with a long-acting benzodiazepine. Desvenlafaxine inhibits neuronal reuptake of both serotonin and norepinephrine to reverse core neurochemical deficits in depression, while clonazepam mitigates acute agitation, panic, and sleep disturbances during therapy induction. Indicated for major depressive disorder with prominent anxiety and severe somatic distress.

Etizolam and Propranolol is a psychotropic and autonomic regulator combination pairing a thienodiazepine with a non-selective beta-blocker. Etizolam acts as a full agonist at central GABAA receptors to suppress emotional distress and anticipatory anxiety, while propranolol blocks peripheral beta-adrenergic receptors to eliminate somatic symptoms (tachycardia, palpitations, sweating, tremors). Indicated for situational anxiety, autonomic anxiety manifestations, panic disorder, and tension headache.

Lorazepam is a high-potency, intermediate-acting 3-hydroxy benzodiazepine on the WHO Model List of Essential Medicines. It enhances GABA-mediated synaptic inhibition by binding to GABAA receptors. Because it undergoes direct hepatic glucuronidation to inactive metabolites without intermediate oxidative CYP450 steps, it is the benzodiazepine of choice in patients with hepatic impairment and the elderly. Indicated for short-term management of severe anxiety, insomnia associated with anxiety, acute status epilepticus, and pre-anesthetic sedation.

Midazolam Nasal Spray is an emergency rescue formulation for acute repetitive seizures and status epilepticus. Delivered across the nasal mucosa, it provides rapid systemic absorption directly into cerebral circulation via the olfactory/trigeminal pathway, bypassing hepatic first-pass metabolism to arrest prolonged convulsions within minutes. Indicated for acute treatment of intermittent, stereotypic episodes of frequent seizure activity in patients with epilepsy.

Melatonin is a synthetic chronobiotic hormone identical to endogenous pineal melatonin. It acts as an agonist at high-affinity G-protein coupled MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN) of the hypothalamus. Activation of MT1 promotes sleep onset by dampening neuronal firing in the master circadian clock, while MT2 shifts circadian rhythm phase. Indicated for primary insomnia characterized by poor sleep quality in adults aged 55 and older, delayed sleep phase syndrome, and jet lag.

Etizolam and Escitalopram combines a fast-acting thienodiazepine with a selective serotonin reuptake inhibitor. Etizolam acts rapidly within 30-60 minutes to suppress acute anxiety, muscle tension, and insomnia, while escitalopram normalizes central serotonergic tone to treat chronic depression and anxiety. Indicated for comorbid depression and anxiety, panic disorder, and acute stress disorders.

Etizolam and Escitalopram combines a fast-acting thienodiazepine with a selective serotonin reuptake inhibitor. Etizolam acts rapidly within 30-60 minutes to suppress acute anxiety, muscle tension, and insomnia, while escitalopram normalizes central serotonergic tone to treat chronic depression and anxiety. Indicated for comorbid depression and anxiety, panic disorder, and acute stress disorders.

Etizolam is a thienodiazepine derivative structurally related to benzodiazepines. It acts as a potent full agonist at the GABAA receptor, producing significant anxiolytic, sedative-hypnotic, anticonvulsant, and muscle-relaxant actions with 6- to 10-fold higher potency than diazepam. Indicated for short-term management of generalized anxiety disorder, panic disorder, and insomnia associated with anxiety.

Triclofos Sodium is an orally administered phosphate prodrug of trichloroethanol, the active metabolite of chloral hydrate. It is rapidly hydrolyzed in the intestine and liver to trichloroethanol, which enhances inhibitory GABAergic transmission in the central nervous system, producing rapid, naturalistic sedation without significant respiratory or cardiovascular depression. Indicated for short-term pediatric sedation prior to non-invasive diagnostic procedures (EEG, MRI, CT scans, echocardiograms) and short-term insomnia.

Cyclobenzaprine Hydrochloride is a centrally acting skeletal muscle relaxant structurally related to tricyclic antidepressants. It acts primarily at the brainstem level to reduce tonic somatic motor activity through descending serotonergic and noradrenergic pathways, relieving acute voluntary muscle spasm without interfering with peripheral muscle function. Indicated for short-term relief of muscle spasm associated with acute, painful musculoskeletal conditions.

Zolpidem Tartrate is an imidazopyridine non-benzodiazepine hypnotic agent. It binds selectively with high affinity to the alpha-1 subunit-containing GABAA receptor subtype (omega-1 receptor) in the brain, sparing alpha-2 and alpha-3 subunits, resulting in potent sleep-inducing action with minimal myorelaxant and anticonvulsant effects. Indicated for short-term treatment of insomnia characterized by difficulties with sleep initiation.

Buspirone Hydrochloride is an azaspirodecanedione anxiolytic agent that acts as a high-affinity partial agonist at presynaptic and postsynaptic serotonin 5-HT1A receptors, with moderate affinity for dopamine D2 autoreceptors. Unlike benzodiazepines, it possesses zero affinity for GABAA receptors, producing effective sustained anxiolysis without causing sedation, cognitive impairment, muscle relaxation, anticonvulsant activity, or physical dependence and withdrawal. Indicated for generalized anxiety disorder (GAD) and short-term relief of anxiety symptoms.

Buspirone Hydrochloride is an azaspirodecanedione anxiolytic agent that acts as a high-affinity partial agonist at presynaptic and postsynaptic serotonin 5-HT1A receptors, with moderate affinity for dopamine D2 autoreceptors. Unlike benzodiazepines, it possesses zero affinity for GABAA receptors, producing effective sustained anxiolysis without causing sedation, cognitive impairment, muscle relaxation, anticonvulsant activity, or physical dependence and withdrawal. Indicated for generalized anxiety disorder (GAD) and short-term relief of anxiety symptoms.

Clonazepam and Propranolol is a psychotropic and autonomic regulator combination. Clonazepam provides sustained central anxiolysis and neuronal stabilization via GABAA chloride conductance, while propranolol blocks peripheral beta-adrenergic receptors, stopping autonomic hyperarousal (tremors, racing heartbeat, flushing). Indicated for social phobia, severe panic attacks, stage fright, and anxiety disorders characterized by palpitations and tremor.

Clonazepam and Propranolol is a psychotropic and autonomic regulator combination. Clonazepam provides sustained central anxiolysis and neuronal stabilization via GABAA chloride conductance, while propranolol blocks peripheral beta-adrenergic receptors, stopping autonomic hyperarousal (tremors, racing heartbeat, flushing). Indicated for social phobia, severe panic attacks, stage fright, and anxiety disorders characterized by palpitations and tremor.

Clonazepam and Propranolol is a psychotropic and autonomic regulator combination. Clonazepam provides sustained central anxiolysis and neuronal stabilization via GABAA chloride conductance, while propranolol blocks peripheral beta-adrenergic receptors, stopping autonomic hyperarousal (tremors, racing heartbeat, flushing). Indicated for social phobia, severe panic attacks, stage fright, and anxiety disorders characterized by palpitations and tremor.

Diazepam and Imipramine combines a classical long-acting benzodiazepine with a tricyclic antidepressant (TCA). Imipramine blocks reuptake of norepinephrine and serotonin to treat depression, while diazepam immediately quells panic, anxiety, motor agitation, and insomnia. Indicated for depression accompanied by pronounced anxiety, agitation, or sleep architecture disruption.

Diazepam and Imipramine combines a classical long-acting benzodiazepine with a tricyclic antidepressant (TCA). Imipramine blocks reuptake of norepinephrine and serotonin to treat depression, while diazepam immediately quells panic, anxiety, motor agitation, and insomnia. Indicated for depression accompanied by pronounced anxiety, agitation, or sleep architecture disruption.

Zolpidem and Melatonin is a dual-mechanism sleep regulator combining a non-benzodiazepine positive allosteric modulator with the endogenous pineal chronobiotic hormone. Zolpidem binds selectively to the alpha-1 subunit of the GABAA receptor, rapidly inducing sleep onset within 15-30 minutes, while melatonin acts on MT1 and MT2 receptors in the suprachiasmatic nucleus to synchronize circadian sleep architecture and promote restful sleep maintenance. Indicated for short-term management of sleep-onset and sleep-maintenance insomnia and jet lag/circadian rhythm sleep disorders.

Zolpidem and Melatonin is a dual-mechanism sleep regulator combining a non-benzodiazepine positive allosteric modulator with the endogenous pineal chronobiotic hormone. Zolpidem binds selectively to the alpha-1 subunit of the GABAA receptor, rapidly inducing sleep onset within 15-30 minutes, while melatonin acts on MT1 and MT2 receptors in the suprachiasmatic nucleus to synchronize circadian sleep architecture and promote restful sleep maintenance. Indicated for short-term management of sleep-onset and sleep-maintenance insomnia and jet lag/circadian rhythm sleep disorders.

Opipramol is a tricyclic psychotropic agent that acts uniquely as a high-affinity sigma-1 and sigma-2 receptor agonist, with low-to-moderate affinity for dopamine D2, 5-HT2, and H1 receptors, and no monoamine reuptake inhibition. Produces prominent anxiolytic, calming, and somatic symptom-stabilizing effects. Indicated for generalized anxiety disorder (GAD) and somatoform disorders.

Opipramol is a tricyclic psychotropic agent that acts uniquely as a high-affinity sigma-1 and sigma-2 receptor agonist, with low-to-moderate affinity for dopamine D2, 5-HT2, and H1 receptors, and no monoamine reuptake inhibition. Produces prominent anxiolytic, calming, and somatic symptom-stabilizing effects. Indicated for generalized anxiety disorder (GAD) and somatoform disorders.

Tofisopam is a 2,3-benzodiazepine derivative that differs structurally and pharmacologically from classical 1,4-benzodiazepines. It binds to stereospecific sites in the central nervous system without binding to classical benzodiazepine GABAA binding sites, producing anxiolytic and autonomic stabilizing actions without causing sedation, muscle relaxation, amnesia, motor impairment, or dependence. Indicated for anxiety disorders, somatic neuroses, vegetative dystonia, and alcohol withdrawal anxiety.